Lazaros G A, Papatheodoridis G V, Delladetsima J K, Tassopoulos N C
First Department of Medicine, Western Attica General Hospital, Athens, Greece.
J Hepatol. 1996 Jun;24(6):753-6. doi: 10.1016/s0168-8278(96)80273-x.
Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported. We describe a case of prolonged terbinafine-induced cholestatic liver disease. Extrahepatic cholestasis, viral hepatitis and autoimmune liver disorders were excluded. The histological findings of marked cholestasis without evidence of extrahepatic biliary obstruction or acute hepatitis were compatible with the diagnosis of drug-induced liver disease. Biochemical parameters of liver cell damage returned to normal levels 6 months later.
与口服特比萘芬相关的肝胆疾病鲜有报道。我们描述了一例由特比萘芬引起的胆汁淤积性肝病，病程迁延。已排除肝外胆汁淤积、病毒性肝炎和自身免疫性肝病。显著胆汁淤积的组织学表现，且无肝外胆管梗阻或急性肝炎的证据，符合药物性肝病的诊断。6个月后肝细胞损伤的生化指标恢复至正常水平。
